ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 30.4 | 32.7 | 23.5 |
| Other income | 0.1 | 0.7 | 1.0 |
| Total income | 30.5 | 33.4 | 24.5 |
| Profit before exceptional items & tax | 0.1 | -3.0 | 0.6 |
| Profit before tax | 0.1 | -3.0 | 0.6 |
| Net profit | 1.1 | -3.6 | 1.1 |
| Operating margin | 0.3% | -9.0% | 2.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +0.00% |
|---|---|
| Revenue, year on year | +29.40% |
| Operating profit, year on year | +100.00% |
| Operating profit, quarter on quarter | +100.00% |
BSE results filing, NSE: JHS. Figures extracted from the filing.
JHS Svendgaard Laboratories Ltd: key numbers
- Share price
- ₹8.17
- Market cap
- ₹69.94 Cr
- Revenue (annual)
- ₹101.7 Cr
- Net profit (annual)
- ₹-1.92 Cr
- P/E (TTM)
- -59.1×Sector 41.3×
- Promoter holding
- 33.85%+0.00% QoQ
- FII holding
- 2.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from JHS Svendgaard Laboratories Ltd
All →JHS Svendgaard Laboratories Other Announcement
JHS Svendgaard filed its quarterly Regulation 32 statement on 2024 preferential issue proceeds. Fund allocation shifted toward capex after shareholder approval; no quarter deviation reported.
JHS Svendgaard Laboratories Management Change
JHS Svendgaard Laboratories appointed Mr. Pardeep Kumar Bhardwaj as a Non-Executive Independent Director, effective 2 November 2026, for five years, subject to shareholder approval. Board committee compositions were also reconstituted.
JHS Svendgaard Laboratories Q2 FY27 Results: Turns Profitable, Net Profit ₹0.5 Cr
JHS Svendgaard Laboratories Ltd reported revenue from operations of ₹21.8 Cr (-2.2% YoY) and net profit of ₹0.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹0.5 Cr
JHS Svendgaard Laboratories Board Meeting Date
JHS Svendgaard Laboratories has intimated a Board meeting on 2 November 2026 to approve un-audited Q1/H1 FY27 results. Trading window closed from 1 October 2026.
JHS Svendgaard Laboratories Other Announcement
JHS Svendgaard Laboratories Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) of SEBI LODR Regulations for the quarter ended September 30, 2026.
JHS Svendgaard Laboratories Annual General Meeting
JHS Svendgaard Laboratories held its 22nd Annual General Meeting on September 26, 2026, transacting business related to financial statements and director appointment.